Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWNNASDAQ:GYRENASDAQ:VIRNASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$6.93-0.7%$6.97$6.08▼$16.76$707.51M-1.31.11 million shs828,801 shsGYREGyre Therapeutics$8.58+4.4%$8.91$6.11▼$19.00$804.44M1.9118,069 shs194,550 shsVIRVir Biotechnology$5.28+1.0%$5.41$4.32▼$14.45$722.99M1.241.40 million shs990,956 shsVYGRVoyager Therapeutics$3.32+1.2%$3.22$2.65▼$9.55$183.72M0.95462,036 shs998,767 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals-0.72%+9.83%-7.35%-23.85%-45.73%GYREGyre Therapeutics+4.38%-9.11%-2.61%-19.81%-21.14%VIRVir Biotechnology+0.86%+10.92%-14.15%-34.57%-50.09%VYGRVoyager Therapeutics+1.22%+21.61%-4.87%-19.81%-60.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDAWNDay One Biopharmaceuticals1.8112 of 5 stars3.60.00.00.02.82.50.0GYREGyre Therapeutics0.1352 of 5 stars0.00.00.00.02.51.70.0VIRVir Biotechnology3.0475 of 5 stars3.41.00.00.03.33.31.3VYGRVoyager Therapeutics4.6244 of 5 stars4.62.00.04.61.11.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 3.13Buy$30.57341.15% UpsideGYREGyre Therapeutics 3.00BuyN/AN/AVIRVir Biotechnology 2.86Moderate Buy$32.86522.29% UpsideVYGRVoyager Therapeutics 3.13Buy$13.39303.31% UpsideCurrent Analyst Ratings BreakdownLatest VYGR, GYRE, DAWN, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.004/8/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/13/2025VYGRVoyager TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.003/13/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/12/2025VYGRVoyager TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$12.00 ➝ $10.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$161.92M4.34N/AN/A$3.98 per share1.74GYREGyre Therapeutics$100.64M7.99$0.17 per share50.49$0.18 per share47.67VIRVir Biotechnology$14.30M51.03N/AN/A$11.82 per share0.45VYGRVoyager Therapeutics$66.96M2.74$2.35 per share1.41$5.37 per share0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)GYREGyre Therapeutics-$92.93M$0.02429.00∞N/A-84.57%-118.43%-71.97%8/12/2025 (Estimated)VIRVir Biotechnology-$615.06M-$4.22N/AN/AN/A-678.40%-36.71%-31.00%7/30/2025 (Estimated)VYGRVoyager Therapeutics$132.33M-$1.464.68N/AN/A15.80%8.33%6.15%8/5/2025 (Estimated)Latest VYGR, GYRE, DAWN, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 million3/11/2025Q4 2024VYGRVoyager Therapeutics-$0.35-$0.59-$0.24-$0.59$16.58 million$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A14.6214.55GYREGyre TherapeuticsN/A3.723.29VIRVir BiotechnologyN/A8.948.94VYGRVoyager TherapeuticsN/A8.458.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%GYREGyre Therapeutics23.99%VIRVir Biotechnology65.32%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%GYREGyre Therapeutics19.52%VIRVir Biotechnology16.00%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableGYREGyre Therapeutics4093.76 million75.27 millionNo DataVIRVir Biotechnology580138.24 million116.24 millionOptionableVYGRVoyager Therapeutics10055.34 million52.15 millionOptionableVYGR, GYRE, DAWN, and VIR HeadlinesRecent News About These CompaniesVoyager Technologies, Inc. Announces Launch of Initial Public OfferingJune 3 at 5:51 AM | finanznachrichten.deSpace Firm Voyager Technologies Seeks $1.6 Billion Valuation in IPOJune 2 at 7:49 PM | theinformation.com2001: A Space Odyssey's balletic waltz to be beamed to Voyager 1May 27, 2025 | newatlas.comNASA restarts one of Voyager 1's thrusters after 21 years of inactivityMay 26, 2025 | lemonde.frVestal Point Capital LP Raises Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)May 21, 2025 | marketbeat.comNASA Engineers Revive Long-Dormant Thrusters on Voyager 1, the Farthest Spacecraft From Earth, in a ‘Miracle Save’May 21, 2025 | msn.comVoyager Therapeutics' Role in Biotechnology and Market Trends NASDAQ CompositeMay 20, 2025 | kalkinemedia.comWith 46% ownership, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has piqued the interest of institutional investorsMay 20, 2025 | uk.finance.yahoo.comVoyager Technologies files to go publicMay 19, 2025 | spacenews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from BrokeragesMay 18, 2025 | marketbeat.comVoyager reports breakthrough in brain drug deliveryMay 17, 2025 | uk.investing.comVoyager Therapeutics Publishes Data on ALPL's Role in AAV Transport Across the Blood-Brain BarrierMay 15, 2025 | quiverquant.comVoyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy PublicationMay 15, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Stake Decreased by Bridgeway Capital Management LLCMay 15, 2025 | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Increased by Dimensional Fund Advisors LPMay 13, 2025 | marketbeat.comQ2 EPS Forecast for Voyager Therapeutics Reduced by AnalystMay 13, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for VYGR Q2 Earnings?May 11, 2025 | marketbeat.comWedbush Equities Analysts Boost Earnings Estimates for VYGRMay 11, 2025 | marketbeat.comFarallon Capital Management LLC Has $14.58 Million Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)May 11, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for VYGR FY2029 Earnings?May 10, 2025 | marketbeat.comVoyager Therapeutics, Inc.: Voyager Reports First Quarter 2025 Financial and Operating ResultsMay 9, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYGR, GYRE, DAWN, and VIR Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWN$6.93 -0.05 (-0.72%) Closing price 06/4/2025 04:00 PM EasternExtended Trading$6.90 -0.03 (-0.42%) As of 07:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Gyre Therapeutics NASDAQ:GYRE$8.58 +0.36 (+4.38%) Closing price 06/4/2025 04:00 PM EasternExtended Trading$8.74 +0.16 (+1.92%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Vir Biotechnology NASDAQ:VIR$5.28 +0.05 (+0.96%) Closing price 06/4/2025 04:00 PM EasternExtended Trading$5.33 +0.05 (+0.95%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Voyager Therapeutics NASDAQ:VYGR$3.32 +0.04 (+1.22%) Closing price 06/4/2025 04:00 PM EasternExtended Trading$3.41 +0.09 (+2.71%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause? Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
